🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

V114 (PCV15) offers heightened protection in infants against serotypes 22F and 33F—gaps not covered by PCV13—while maintaining a comparable safety profile. This advancement could enhance early immunity in pediatric vaccination programs. Read more: hubs.li/Q03r1_5K0

#HHS has canceled over $600 million in mRNA bird flu vaccine funding for Moderna’s H5N1 project, citing safety and testing concerns—despite promising trial results. Experts warn this may compromise future pandemic preparedness. Read more: hubs.li/Q03r52Bg0

#NLASessions: Phase 2 RNA-based therapies achieved up to 94% reduction in lipoprotein(a) at 36 weeks, while a small-molecule agent cut levels by ~65%. These novel approaches may substantially lower residual cardiovascular risk in ASCVD. Read more: hubs.li/Q03r25Nb0

#ASCO25: The phase 3 SERENA‑6 trial showed that camizestrant + a CDK4/6 inhibitor halved the risk of progression or death (HR 0.44), boosting median PFS from 9.2 months to 16.0 months in ESR1‑mutated, HR+/HER2− advanced breast cancer. Read more: hubs.li/Q03r28Sd0